News & Events

Award wins for College Hill Clients: November

Award wins for College Hill Clients: November

21 November 2013, London, Manchester, Munich and Melbourne: November was a good month for award wins for College Hill Life Sciences’s clients, with Prosensa winning the Best SME Biotech Pipeline at the 2nd Annual Rare & Orphan Advocacy and Research (ROAR) Awards and Mesoblast winning Financial Deal of the Year at the 9th Annual SCRIP Awards.

Prosensa (NASDAQ: RNA), the Dutch biopharmaceutical company focused on rare diseases with a high unmet medical need, was honored for the breadth and depth of its orphan drug pipeline, most notably its pioneering work in Duchenne muscular dystrophy.

The ROAR Awards were announced at a Gala Dinner and Award Ceremony during the 4th Annual World Orphan Drug Congress Europe, November 14-15, 2013, in Geneva, Switzerland. The ROAR Awards are an opportunity to recognize and honor achievements by organizations and individuals from industry, patient, and rare disease advocacy communities.

“There is a desperate unmet need in rare diseases, and we are dedicated to developing treatments for patients who face very limited options,” said Hans Schikan, CEO of Prosensa. “We are honored to accept this award and would like to thank the judging committee for recognizing our efforts, and our many partners and advocates for their steadfast support.”

For the full list of winners and photos from the ROAR Awards, please click here.

The 9th Annual SCRIP Awards were held at London’s Lancaster Hotel and hosted by journalist and broadcaster Justin Webb. The awards seek to highlight industry achievements across the full range of business activities. Financing Deal of the Year was awarded to Mesoblast for its raising of AUS$170m in March this year, the biggest biotechnology equity financing of 2104 at that point, in an upsized transaction. The financing took place in just 48 hours, taking Mesoblast’s cash reserves to AUS$332m and allowing it to pursue its twin goals of developing its pipeline of stem cell-based products for regenerative medicine and expanding its global shareholder base.

For the full list of finalists and winners, please click here.

back to news


Melanie Toyne-SewellManaging Partner